Abstract
The Authors review and critically discuss the most recent published evidence on treatment of mild-moderate ulcerative colitis both in the induction and maintenance of remission. Evidence on each drug is introduced by the related statement of ECCO guidelines. A brief introduction on disease classification and the need of standardizing indexes of clinical and endoscopic activity is also provided. Concluding remarks stress the heterogeneity of available studies both in the selection of patients and the outcomes evaluated and suggest the development of an international consensus in setting standards which will allow studies’ results to be compared and combined to produce high quality clinical recommendations.
Keywords: Ulcerative colitis, treatment, controlled clinical trials
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
23